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Background: Alzheimer’s disease (AD) is the most common form of dementia, characterized by progressive
cognitive impairment and neurodegeneration. However, despite extensive clinical and genomic studies, the
molecular basis of AD development and progression remains elusive.
Methods: To elucidate molecular systems associated with AD, we developed a large scale gene expression
dataset from 1053 postmortem brain samples across 19 cortical regions of 125 individuals with a severity
spectrum of dementia and neuropathology of AD. We excluded brain specimens that evidenced
neuropathology other than that characteristic of AD. For the first time, we performed a pan-cortical brain region
genomic analysis, characterizing the gene expression changes associated with a measure of dementia severity
and multiple measures of the severity of neuropathological lesions associated with AD (neuritic plaques and
neurofibrillary tangles) and constructing region-specific co-expression networks. We rank-ordered 44,692
gene probesets, 1558 co-expressed gene modules and 19 brain regions based upon their association with
the disease traits.
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Results: The neurobiological pathways identified through these analyses included actin cytoskeleton, axon guidance,
and nervous system development. Using public human brain single-cell RNA-sequencing data, we computed brain cell
type-specific marker genes for human and determined that many of the abnormally expressed gene signatures and
network modules were specific to oligodendrocytes, astrocytes, and neurons. Analysis based on disease severity
suggested that: many of the gene expression changes, including those of oligodendrocytes, occurred early in the
progression of disease, making them potential translational/treatment development targets and unlikely to be mere
bystander result of degeneration; several modules were closely linked to cognitive compromise with lesser association
with traditional measures of neuropathology. The brain regional analyses identified temporal lobe gyri as sites
associated with the greatest and earliest gene expression abnormalities.
Conclusions: This transcriptomic network analysis of 19 brain regions provides a comprehensive assessment of the
critical molecular pathways associated with AD pathology and offers new insights into molecular mechanisms
underlying selective regional vulnerability to AD at different stages of the progression of cognitive compromise and
development of the canonical neuropathological lesions of AD.
Keywords: Alzheimer’s disease, Dementia, Differential expression, Gene co-expression network, Gene module, Systems
biology, Selective vulnerability, Demyelination, Brain cell typesBackground
Alzheimer’s disease (AD) is a complex neurodegenerative
disease characterized by accumulation of amyloid plaques
and neurofibrillary tangles (NFT) in the brain [1–3]. The
development of AD causes irreversible and progressive
loss of neurons resulting in cognitive impairment and ul-
timately dementia [4, 5]. As the disease progresses, more
and more areas of the brain become damaged but AD
does not affect all brain regions simultaneously or uni-
formly [6]. Some brain regions are more vulnerable to AD
than others [7, 8]. Yet, the molecular basis of AD develop-
ment and progression remains elusive.
Whole transcriptome analyses have shown much prom-
ise in understanding how altered gene expression contrib-
utes to complex diseases such as cancer [9], obesity [10],
schizophrenia [11], and neurodegenerative disorders [12,
13]. The unbiased quantification and bioinformatic ana-
lysis of genome-wide RNA expression provides insights
into biological pathways that regulate cellular processes
and disease progressions at the molecular level. Transcrip-
tome analysis has been widely applied to investigate the
pathogenesis of AD in mouse models [14, 15] and human
postmortem brain tissues [16–18]. Analysis of gene ex-
pression abnormalities in the human postmortem brain
affected to greater or lesser degrees can identify genes and
pathways dysregulated by AD. However, the power of
transcriptomic analysis is hindered by the analysis of very
limited number of brain regions and restricted severity
stages in the previous studies of AD.
Although complex human diseases such as AD likely re-
sult from the interplay of many genetic and environmental
factors involving thousands or tens of thousands of tran-
scripts and proteins, core features of the disease can be
characterized by studying affected molecular networks
through the cognitive and neuropathological progressionof the disease [19]. Gene co-expression network analysis
approaches have been developed to capture interactions
among genes and to identify higher order network struc-
tures such as modules comprising highly interconnected
genes. Using a dataset consisting of gene expression
profiles from laser-captured neurons from the middle
temporal gyrus, entorhinal cortex, hippocampus, and pos-
terior cingulate cortex from 34 AD patients and 13 con-
trols [20], Ray and Zhang [21] constructed co-expression
networks and found differential connectivity between
region-specific networks enriched for two broad categor-
ies of functional pathways: inflammation/immune-related
pathways and cytoskeleton remodeling pathways. More
recently, Zhang et al. [18] performed a multiscale gene
network analysis (MNA) of a much larger cohort of hu-
man brain specimens from dorsolateral prefrontal cor-
tex (PFC), visual cortex (VC), and cerebellum (CB) in
376 AD patients and 173 non-demented controls. MNA
revealed many facets of the molecular-interaction struc-
tures in AD and formally rank-ordered gene subnet-
works based on their relevance to AD pathological and
clinical traits. Using less sophisticated analytical ap-
proaches, Haroutunian et al. [16] staged regional tran-
scriptional dysregulation based on the severity of global
cognitive compromise.
In this study, we significantly expand the characterization
of molecular networks associated with AD across multiple
brain regions by generating and then analyzing a large-
scale transcriptomic dataset [16] from 1053 postmortem
brain tissues spanning 19 brain regions from 125 subjects
with a full spectrum of AD severity in brains devoid of
AD-unrelated confounding neuropathologies, such as cere-
brovascular disease. Gene co-expression network analysis
was applied to these data to identify subnetworks that were
dysregulated in AD and/or associated with AD pathology.
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of dysregulation and association to AD to discover novel
pathways and key genes that may serve as effective targets
for therapeutic intervention.
Methods
Microarray gene expression profile and data
preprocessing
The RNA samples collected from the current Mount
Sinai Medical Center Brain Bank (MSBB) AD cohort
were profiled on two Affymetrix microarray platforms,
Human Genome (HG) U133A and U133B, except in two
brain regions, amygdala (AMYG) and nucleus accum-
bens (NAc), for which the Affymetrix HG U133 Plus 2.0
array was used. Since there were a limited number of
common probesets between HG U133A and HG U133B,
the probesets from the two platforms were merged in
the analyses, with signals of common probesets aver-
aged. Affymetrix HG U133 Plus 2.0 includes all probe-
sets on U133A and U133B and 9921 additional
probesets representing approximately 6500 additional
genes. The array probes were annotated according to the
Ensembl version 72 (genome build GRCh37.p11; June
2013) using the R/Biomart library. The raw microarray
data were first quantile normalized with all probesets on
the arrays by making use of the RMA [22] method im-
plemented in the R/Bioconductor package affy (v1.44)
with the default parameters and then corrected for co-
variates including sex, postmortem interval (PMI), pH,
and race using a linear regression model.
An integrative network approach to analyze the MSBB data
We applied an integrative network-based approach to
identify critical genes and gene networks associated with
AD in 19 brain regions (Fig. 1a and b). We first identified
gene signatures associated with clinical/neuropathological
outcomes through differential expression (DE) and gene-
trait correlation analyses. We tested enrichment of cell
type-specific genes in the DE signatures and rank-ordered
brain regions in relevance to AD by the number of gene
signatures associated with different clinical/neuropatho-
logical traits. Next, we computed gene-gene correlations
and performed hierarchical clustering analysis to con-
struct co-expression networks for each brain region. Based
on the network modules identified in individual brain re-
gions, we constructed a meta-co-expression network to
assess the correlation of networks between brain regions.
Then we rank-ordered the co-expression network mod-
ules across all brain regions by multiple features. We
evaluated the network module topology using gene per-
turbation signatures. Then, for top modules, we tested the
replication of the network modules in an independent
dataset from the Harvard brain bank. Later, we examined
the cell type specificity and enrichment of genetic signalof the top ranked modules by using AD susceptibility
genes and Aβ pathway genes. Finally, we explored regional
selective vulnerability to the disease with two example
pathways.
Differential expression analysis
We first computed the correlations between gene ex-
pression and six neuropathological or cognitive traits,
including clinical dementia rating (CDR), Braak stage,
Consortium to Establish a Registry for Alzheimer’s Dis-
ease (CERAD) diagnostic certainty, plaque density mean,
sum of neuritic plaque (NP) density estimates, and sum
of NFT density estimates. For each trait, the samples
were classified into three groups according to the disease
status and severity staging defined by the trait: normal,
low severity, and high severity. Additional file 1: Table
S1 tabulates the complete sample demographic informa-
tion and Additional file 1: Table S2 shows the criteria for
defining these disease staging groups with respect to
each trait. We applied a linear model analysis to identify
genes differentially expressed among the disease staging
groups by using R package Limma (v3.26.9) with default
parameters [23]. To adjust for multiple tests, false dis-
covery rate (FDR) was estimated by fitting the same
Limma linear models after repeatedly reshuffling sam-
ple group labels (five times) to derive an empirical null
distribution of the test statistics (limma moderated t-
statistics), and then FDR at a cutoff was estimated as
FDR = n × (FP/N)/P, where P denotes the number of sig-
nificant tests at a given cutoff in the non-permuted
data, n is the number of tests in the non-permuted
data, FP is the number of false positives at a given cut-
off from the permutation, and N is the total number of
tests in permutation. This procedure is essentially the
same as first computing empirical P values based on a
null distribution from permutation and then applied
Benjamini–Hochberg’s (BH) FDR control [24] with the
empirical P values. Probesets with a FDR less than 0.05
and fold change (FC) larger than 1.5 were considered
significant.
Correlations between gene expression and cognitive/
neuropathological traits
Complementing the differential expression analysis
defined above, we carried out correlation analyses to
identify gene expression traits that were positively or
negatively correlated with each of the six cognitive/
neuropathological traits described above. Since CDR,
Braak, and CERAD were measured as discrete ordinal
scores, Spearman’s rank correlation coefficient analysis
was used to compute the strength of correlation between
these clinical/neuropathological traits and gene expres-
sion traits. FDR was estimated by first computing a null
distribution of Spearman’s correlation coefficients through
Fig. 1 Data generation and analysis flow. a Schematic illustration of the 19 brain regions profiled in the current study. The numbered areas
highlighted in yellow are the Brodmann (BM) areas, while the arrows indicate caudate nucleus (CD), nucleus accumbens (NAc), putamen (PT),
amygdala (AMYG), and hippocampus (HIPP), respectively. b An overview of the analysis flow. RNA samples from 19 brain regions of 125 MSBB
specimens were collected and profiled using Affymetrix Genechip microarrays. From the microarray RNA expression data, we first identified gene
signatures associated with cognitive/neuropathological outcomes through differential expression and gene-trait correlation analyses. We
tested enrichment of cell type-specific genes in the differentially expressed gene signatures and rank-ordered brain regions in relevance to AD
by comprehensively comparing the number of gene signatures identified in each region for each trait. Next, we constructed a gene co-expression
network for each brain region. Based on the network modules identified in individual brain regions, we constructed a meta-co-expression network to
assess the correlation of networks between brain regions. Then we rank-ordered the co-expression network modules across all brain regions by
multiple features. We evaluated the network module topology using gene perturbation signatures. Then, for top modules, we tested the replication of
the network modules in an independent dataset from the Harvard brain bank. Later, we examined the cell type specificity and enrichment of genetic
signal of the top ranked modules by using AD susceptibility genes and Aβ pathway genes. Finally, we explored regional selective vulnerability to the
disease with two example pathways
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applying a similar FDR control procedure as described in
differential expression analysis. We used a FDR of 0.05 as
the significance threshold.
Accessing brain cell type-specific gene signatures
To characterize if certain brain cell types were dysregu-
lated in disease, we computed a panel of cell type-
specific genes for five major brain cell types, includingastrocytes, endothelial, neurons, microglia, and oligoden-
drocytes by making use of a large scale human brain single-
cell RNA-sequencing (RNA-seq) dataset [25]. We down-
loaded RNA-seq read count data from GEO (accession no.
GSE67835) and selected samples corresponding to the five
major brain cell types: astrocyte, endothelial, microglia,
neuron, and oligodendrocyte. Genes with less than 50 reads
across all samples were discarded. The remaining gene
count data were analyzed by a Bayesian negative binomial
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sion (or library size), and subject source incorporated
as predictors by making use of the RStan source code
provided in [26]. Using numerical samples obtained by
Markov chain Monte Carlo (MCMC), we calculated the
posterior probability that gene expression was enriched
in one cell type compared to basal expression given by
the regression. A gene was considered cell type-specific
if it met two criteria: (1) it was enriched with 99.9 %
posterior probability in one cell and not enriched in
any other cells; and (2) its expression in the enriched
cell was on average fivefold larger than basal expression
in the numerical samples. The inferred brain cell type-
specific gene signatures are provided in Additional file
1: Table S3.
Set enrichment analysis
Set enrichment analysis (or set overlap test) was carried
out using Fisher’s exact test assuming the sets of genes,
such as differentially expressed genes (DEGs), module
genes, and network neighbors, were identically inde-
pendently sampled from the genome-wide genes pro-
filed by the array. To control for multiple testing, we
employed the BH approach to constrain the FDR. For
functional enrichment analysis of signature genes, the
gene ontology (GO) annotations and canonical path-
ways (Biocarta, KEGG and Reactome) gene sets were
obtained from the Molecular Signatures Database
(MSigDB) v4.0 [27].
Co-expression network analysis
Weighted gene co-expression network analysis (WGCNA)
[28] was performed to identify the gene modules with
coordinated expression patterns for each brain region.
Briefly, Pearson’s correlation coefficients were calcu-
lated between all pairs of probesets after microarray
data normalization. Next, the correlation matrix was
converted into an adjacency matrix using a power func-
tion f(x) = xβ, where x was the element of the correl-
ation matrix and parameter β was determined such that
the resulting adjacency matrix was approximately scale-
free [28]. In the present study, we used β = 6 with other
parameters set by default and this led to a truncated
scale-free index greater than 0.95 for all the 19 co-
expression networks. The adjacency matrix was subse-
quently transformed into a topological overlap matrix
(TOM) [29] which captured both the direct and indir-
ect interactions between a pair of probesets. Average
linkage hierarchical clustering was then employed to
cluster probesets based on the TOM. Finally, a tree cut-
ting algorithm [30] was used to dynamically cut the
hierarchical clustering dendrogram branches into
highly connected modules, each of which was assigned
a distinct color code. The whole network constructionprocedure was based on an R package WINA, a computa-
tionally optimized version of the WGCNA package.
Sort brain regions and network modules using an
ensemble ranking metric
For each clinical/neuropathological trait, we had per-
formed differential expression between any pair of disease
severity groups and also called trait associated genes
(TCGs). The number of DEGs (or TCGs) identified from
different brain regions could be regarded as a variable (or
feature) for ranking order the brain regions in relevance to
the variation of a particular trait. In total, there were 24
variables useful for ranking: six sets of TCGs, and 18 sets
of DEGs including three sets (i.e. medium versus low, high
versus medium, and high versus low) from each of the six
traits. To congregate rankings from all 24 variables, we
proposed to compute a composite importance score of a




j ¼ 1f K ij
  1=n
where n = 24 denotes the number of ranking variables,
Kij denotes the number of genes identified for ith brain
region regarding jth ranking variable, and f is a trans-
formation function. Here we used log transformation
function as it can shrink the gene counts of different
variables to a more comparable scale. The choice of f is
beyond the scope the present study. Then the composite
importance scores were scaled to be in the range of 0–1
by dividing the maximum score. Finally, the brain region
with the highest composite importance score was ranked
in the top, while the brain region with the lowest com-
posite importance score was ranked in the bottom.
We applied the above ensemble ranking metric to rank-
order co-expression network modules. For each module,
the ranking variables included the P values of strength of
correlations between module eigengene expression and
clinical/neuropathological traits and P values of enrich-
ment for DEGs and TCGs. We used minus log as the
transformation function for P values.
Results
Development of a large AD cohort
A total of 125 human brains were accessed from the
Mount Sinai/JJ Peters VA MSBB cohort, which holds
over 1800 well-characterized brains. This cohort was
assembled after applying stringent inclusion/exclusion
criteria and represents the full spectrum of clinical and
neuropathological disease severity in the absence of
discernable non-AD neuropathology. All neuropsycho-
logical, diagnostic and autopsy protocols were approved
by the Mount Sinai and JJ Peters VA Medical Center
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ments, cognitive, and medical and neurological status
determinations were performed according to previously
published procedures as described in detail [16]. For
each sample, a number of cognitive and neuropathological
outcomes were recorded and analyzed herein, including
CDR, Braak (Braak NFT score) [31, 32], CERAD diagnoses
and ratings of pathology (Consortium to Establish a Regis-
try for Alzheimer’s Disease diagnosis) [33], plaque density
mean (PLQ_Mn, average of NP counts in five cardinal
cortical regions), sum of neuritic plaque density estimates
(NPrSum, sum of CERAD semi-quantitative rating scores
for all cortical regions examined neuropathologically), and
sum of neurofibrillary tangles density estimates (NTrSum,
sum of semi-quantitative NFT density ratings for all cor-
tical regions examined). Detailed sample demographic in-
formation is provided in Additional file 1: Table S1 and a
brief description of the cognitive and neuropathological
traits is provided in Additional file 1: Table S2a.
RNA samples from 19 brain regions (Fig. 1a) isolated
from the 125 MSBB specimens were collected and pro-
filed using Affymetrix Genechip microarrays as described
in “Methods” (Additional file 1: Table S2b). RNA quality
was assessed using a combination of a 260/280 ratio
derived from a high resolution electrophoresis system
(LabChipTM, Agilent Technologies, Palo Alto, CA, USA)Fig. 2 Correlations among age, cognitive, and neuropathological traits. The n
between row and column variables, with color intensity indicating the P valueand 3’–5’ hybridization ratios for glyceraldehyde-3-
phosphate (GAPDH) probes. Not all brain regions for all
subjects were available for analysis. There was an average
of 55 subjects per brain region with varying degrees of AD
pathological and cognitive abnormalities. After data pre-
processing, we used an integrative network approach to
identify critical genes and gene networks associated with
AD (see “Methods” and Fig. 1b for details).
Correlation analysis of cognitive and neuropathological
traits
Figure 2 shows the Spearman correlation coefficients
among age and the cognitive and neuropathological
traits analyzed across all samples. All neuropathological
traits were highly positively correlated with the cognitive
status outcome CDR, which is consistent with both
NFTs and NP being strongly associated with cognitive
decline in AD [3]. Age was not correlated with any of
the cognitive and neuropathological traits at a threshold
of 0.01 for correlation P value. Though it is known that
the gene expression and some indices of neuropathology
might be related to age, we chose not to correct for age
for two reasons. First, age is a risk factor to AD and cor-
rection for age would lose/weaken disease signal. Sec-
ond, more than 81.4 % of the genes differentially
expressed regarding disease traits in age un-correctedumber in each cell indicates the Spearman’s correlation coefficient
at minus log 10 scale
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not shown), suggesting that the impact of age on the
analysis is very small in this study.
Differential expression analysis
For each cognitive or neuropathological trait, we separated
samples into three groups, normal, low disease severity,
and high disease severity (Additional file 1: Table S2c) and
then performed differential gene expression between any
two groups for every brain region using a linear model
analysis. We followed previous practices to subdivide sam-
ples regarding Braak tangle staging (0–2, 3–4, and 5–6)
[34], CDR (0, 0.05–2, 3–5) [16], and CERAD (normal,
possible or probable AD, definite AD) [16, 35]. To the best
of our knowledge, we are the first to systematically analyze
gene expression changes associated with the three neuro-
pathological quantitative traits, plaque density mean, sum
of NP density estimates across multiple cortical regions,
and sum of NFT density estimates across multiple cortical
regions. For each of these three traits, we assigned clean
brains (without plaque or tangle) as normal and then di-
vided the remaining brains into low and high severity
groups with roughly equal numbers of sample size. At a
FDR of < 0.05 and FC > 1.5, we detected a total of 6037
probesets across 19 brain regions and six traits (Additional
file 1: Table S4a). Additional file 1: Figure S1a illustrates
the number of DEGs. The number of DEGs varied greatly
between the different brain regions and traits. For
example, DEGs were detected in 11 brain regions when
stratification was based on cognitive status (CDR) while
DEGs were detected in only two brain regions for sum of
NFT density estimates. Of course, the absolute numbers
of brain regions associated with any given trait varied
depending on the FDR and FC thresholds set.
A number of 34 AD risk genes have been identified so
far, including APOE, APP, BIN1, PSEN1, PSEN2, and
TREM2 (reviewed in [36]). We studied whether these
genes were dysregulated in low and/or high severity status
as defined by each of the six cognitive/neuropathological
traits. As shown in Additional file 1: Table S4b, different
brain regions showed different patterns of gene expression
dysregulation emerged for PSEN1, MEF2C, PICALM, and
PLD3 depending on the cognitive or neuropathological
trait under investigation. The brain regions significantly
associated with altered expression of the transcripts of
these genes included the inferior temporal gyrus (BM20),
the middle temporal gyrus (BM21), and the inferior and
superior frontal gyri (BM44 and BM8).
We next tested whether specific GO and functional
pathway terms were enriched within the DEG signatures
using the MSigDB gene annotation database (Fig. 3 and
Additional file 1: Tables S5a and b). The DEGs, especially
the downregulated genes, between the high and low Braak
neuropathology stage in the superior frontal gyrus (BM8)and the middle temporal gyrus (BM21), presented the
most significant enrichment of signaling pathways such as
GPCR pathway, calcium signaling, neurotrophin signaling,
opioid signaling, epithelial signaling, and GnRH signaling.
As expected, several well-established pathways such as
GABA A receptor activation, neuronal systems, neuro-
transmitter receptor binding, and synaptic transmission
were associated with some disease severity traits in mul-
tiple brain regions. However, these pathways may change
in different directions (i.e. upregulation and downregula-
tion) in different brain regions. For example, the synaptic
transmission pathway was enriched for the downregulated
genes between high and low Braak stages and between
severe and minor dementia, but this same pathway was
enriched for upregulated genes during early stages of
disease, i.e. low Braak stage versus controls or low CERAD
versus normal brain in the superior frontal gyrus (SFG) or
the superior parietal lobule (SPL). Although additional
molecular studies in postmortem human brain and animal
studies are needed to confirm these complex relationships,
the results described here are consistent with a hypothesis
of compensatory upregulation of genes in this pathway in
early disease states followed by their significant downregu-
lation as the disease progresses.Neuron-specific, oligodendrocyte-specific, and astrocyte-
specific genes were most enriched in the DEG signatures
In complex neurodegenerative diseases such as AD, there
is mounting evidence that the different cell types that
comprise the human brain are targeted differentially and
may be affected at different stages of the disease. To inter-
rogate if particular cell types were more or less susceptible
to dysregulation, we compiled a number of gene signa-
tures specific for astrocytes, endothelial cells, microglia,
neurons, and oligodendrocytes (see “Methods”). As ex-
pected, using Fisher’s exact test, we found the gene signa-
tures specific to neurons were most significantly enriched
in the DEGs identified in multiple regions with respect to
multiple traits (Additional file 1: Table S6 and Fig. 4). The
neuron specific genes were primarily enriched for down-
regulated gene signatures of high versus low with respect
to the traits Braak in regions BM8-SFG and BM21-MTG,
CDR in regions BM7-SPL, BM8-SFG, BM44-IFG, and HIPP,
CERAD in region BM44-IFG, and plaque density mean in
regions BM32-AC and BM46-PFC. The neuronal specific
genes were also found to be enriched for upregulated genes
of high versus low when comparing plaque density mean in
BM44-IFG and sum of NP density estimates in BM17-
OVC, low versus normal for trait CERAD in BM7-SPL and
Braak in BM8-SFG. Not surprisingly, astrocyte-specific
genes followed a similar pattern of enrichment for up-
regulated genes in high versus low comparisons with
respect to CDR in BM44-IFG and BM7-SPL.
Fig. 3 Heat map showing the top functional pathways enriched in the DEGs identified between low and normal severity groups and between
high and low severity groups with respect to each of the six cognitive/neuropathological traits. The heat map color intensity denotes the
statistical significance of the enrichment as calculated from Fisher’s exact test after correction for multiple tests
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such as UGT8, which encodes a key enzyme involved in
lipid biosynthesis in myelinating oligodendrocytes, were
also enriched for DEGs as a function of brain region
and disease severity. For example, the oligodendrocyte-
specific genes were significantly enriched with upregu-
lated DEG signatures when comparing CERAD or
Braak stage low to normal in the ITG (BM20) and the
SFG (BM8), respectively. These observations indicate
that oligodendroglials become involved relatively early
during the disease process, when neuron-specific DEGs
are also upregulated (see above), and that their involve-
ment may not necessarily be a natural consequence of
axonal degeneration.
Gene-trait correlation analysis
Complementing the differential expression signatures
comprising expression traits that vary between severity
groups defined by each trait, we also identified TCGs
whose expression levels were positively or negativelycorrelated with the cognitive and neuropathological vari-
ables through Spearman’s rank correlation analysis. TCG
analysis aimed to identify genes showing trend-like
expression response to disease progress that may be
otherwise missed by differential expression analysis.
Additional file 1: Table S7 lists the 1215 TCGs identified
at a FDR threshold of 0.05 for each of the six traits. As
illustrated in Additional file 2: Figure S1b, the number of
TCGs varied dramatically across brain regions and traits.
More than 84 % of the TCGs were identified from three
brain regions for three different traits, including 759
TCGs from the putamen (PT) associated with CDR, 150
TCGs from the region of parahippocampal gyrus
(BM36-PHG) associated with mean cortical neurotitc
plaque density (PLQ-Mn), and 118 TCGs from the
superior temporal gyrus (BM22-STG) associated with
the sum of cortical neurofibrillary tangle density ratings
(NTrSum). The most significant TCG is METTL13
(methyltransferase like 13), which was correlated with
sum of NFT density estimates in the superior parietal
Fig. 4 Cell type specificity of the DEG signatures identified between low and normal severity groups and between high and low severity groups
for each of the six cognitive/neuropathological traits. The heat map color intensity denotes the statistical significance of the enrichment as calculated
from Fisher’s exact test after correction for multiple tests
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protein product encoded by this gene is the antiapopto-
tic protein FEAT, which is also aberrantly overexpressed
in various human cancer tissues [37]. Among the list of
the top trait correlated genes is AKT2, which encodes a
serine/threonine-protein kinase Akt. The Akt kinase is a
downstream mediator of the PI3K pathway and can
phosphorylate a wide range of transcription factors and
kinases such as GSK-3β. Akt regulates multiple bio-
logical processes including cell signaling, cell survival,
proliferation, growth, and glycogen metabolism and the
PI3K/AKT/GSK-3β has been shown to be implicated in
multiple studies of AD including hyper-phosphorylation
of Tau [38].
The GO categories and functional pathways significantly
overrepresented in the TCGs are summarized in Add-
itional file 1: Table S8. At a FDR threshold of 0.05, we only
identified functional enrichment for the TCGs negatively
correlated with dementia severity (CDR) in the PT. The
most significant functional terms include several energy
metabolism related pathways and cellular components,
such as oxidative phosphorylation, TCA cycle and respira-
tory electron transport, and mitochondria. Increasing evi-
dence implicates a role for mitochondrial dysfunction and
oxidative damage in the pathogenesis of AD [39–41]. One
possible mechanism of oxidative stress pathogenesis in
AD is that abnormal mitochondria produced prominent
neuronal oxidative stress in the surrounding cytoplasm
which caused cytoplasmic damage in susceptible neurons[42]. Alternatively, it has been argued that the pathogen-
esis of AD is, at least in part, associated with reduced en-
ergy metabolism [43]. It is noteworthy that mitochondrial
abnormalities have been linked to CDR in previous studies
[44, 45]. Several neurodegenerative disease gene sets are
also enriched in the TCGs negatively correlated with CDR
in the PT, including the Parkinson’s disease KEGG path-
way (fold enrichment (FE) = 5.6, FDR adjusted P value =
3.5 × 10–4), the Huntington’s disease KEGG pathway (FE
= 6.3, FDR adjusted P value = 2.8 × 10–3), and the AD
KEGG pathway (FE = 5.0, FDR adjusted P value = 0.011).
Brain region interaction and ranking in relevance to AD
We have computed the interactions among brain regions
by the pairs of correlated microarray probesets between
any two brain regions. As illustrated in Fig. 5a, strong
interactions were detected between several brain regions
with strong physical interconnectivity. For example, the
PT and caudate nucleus (CD), two closely linked regions
in the dorsal striatum that form the main components
of the basal ganglia, presented more than 8.8 million
significant probeset pairs which accounted for 0.4 % of
the total number of probeset pairs at FDR of 0.05. Simi-
larly, the parahippocampal gyrus (BM36-PHG) and the
temporal pole (BM38-TP), two adjacent regions located
in the temporal lobe, presented 7.9 million significantly
correlated probeset pairs. Strong interactions were also
found between the middle temporal gyrus (BM21-MTG)
and the hippocampus (HIPP), between the anterior
Fig. 5 Brain regions rank-ordered by the relevance to AD pathology. a Brain regions rank-ordered by the number of DEGs and TCGs with respect
to six cognitive/neuropathological traits. From outside to inside, the bar chart in the first track shows the scaled ranking scores with the bar
height proportional to the ranking score, the heat maps in tracks 2–7 show the ranking of regions by the number of DEGs between high and normal
severity groups with respect to the traits CDR, Braak, CERAD, plaque density mean, sum of NP density estimates, and sum of NFT density estimates, re-
spectively; the heat maps in tracks 8–13 show the ranking of regions by the number of TCGs for traits CDR, Braak, CERAD, plaque density mean, sum of
NP density estimates, and sum of NFT density estimates, respectively; while the size and color intensity of the ribbons in the center show the number
of correlated gene pairs at FDR < 0.05 between any two brain regions. The legend color intensity shows the number of DEGs/TCGs with respect to a
trait at log scale. b The locations of the top ranked brain regions in (a) are highlighted by a dotted line
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terior cingulate gyrus and the parahippocampal gyrus.
Based on the differential gene expression and gene-
trait correlation, we could rank-order brain regions in
relevance to AD by comparing the number of DEGs and
TCGs identified in each brain region with respect to
cognitive or neuropathological trait. Using an ensemble
ranking metric that congregates rankings from multiple
sorting features as described in “Methods,” we ranked
the 19 brain regions as shown in Fig. 5a. While sample
sizes were different among the brain regions, which, as a
result, might impact the power in detecting the DEGs
and TCGs, we found this was not the case in the current
dataset as ranking score and sample size were not corre-
lated (Pearson’s correlation coefficient = 0.18, P = 0.458).
Several regions from the temporal lobe were ranked at
the top, including the majority of the temporal cortical
regions examined (Fig. 5a and b). The top ranked tem-
poral cortex from this analysis is consistent with the
roles of the temporal cortex in cognitive processes (e.g.perception of sensory input (visual, auditory, olfactory,
and gustation), language comprehension, and memory
formation and recall) as well as neuroimaging and
neuropathological findings that identify the temporal
lobe as the brain region closely associated with demen-
tia onset and the earliest stages of AD and mild cogni-
tive impairment [46, 47]. This study is perhaps the first
effort to provide a comprehensive and objective ranking
of many brain regions involved in AD based on un-
biased molecular evidence and underscores the signifi-
cance of several regions in temporal lobe to AD and its
etiopathogenesis.
Gene co-expression network analysis
AD, like many other phenotypes, is a complex process
involving dysregulation of genes in different pathways.
Since genes within the same pathway may show similar
expression profiles, we employed weighted gene co-
expression network analysis (WGCNA) to capture the
coordinated gene expression for each brain region
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heat maps of topological overlap matrix (TOM) plots
(Additional file 2: Figure S2). In each of the TOM plots,
the rows and columns represent the same set of genes
sorted by the hierarchical clustering tree of TOM with
modules represented by colored labels. The number of
modules identified from different brain regions ranged
from 56 in the frontal pole (BM20-ITG) to 111 in the
precentral gyrus (BM4-PCG). The fraction of genes that
were successfully assigned into modules was quite simi-
lar: 79.3 ± 7 %.
The co-expression network modules were annotated
with functional categories using gene set enrichment ana-
lysis. The top functional terms for each of the network
modules are listed in Additional file 1: Table S9. Across all
of the network modules, peptide chain elongation and
ribosome genes were the most significantly enriched func-
tional pathways. In fact, peptide chain elongation and
ribosome were significantly enriched in at least one mod-
ule in each of the 19 gene co-expression networks. For ex-
ample, 65 of the 82 genes in module chocolate of brain
region superior temporal gyrus (BM22-STG) were anno-
tated with the peptide chain elongation pathway, resulting
in more than 192-fold enrichment (FDR = 3.19 × 10–147).
Peptide chain elongation is the process of linking to-
gether amino acids to extend the growing protein chain
during protein biosynthesis in the ribosome. How these
peptide chain elongation or ribosome enriched molecu-
lar processes influence the AD phenotype remains to
be elucidated. Among the top functional categories
were a number of immune response pathways, e.g. im-
mune system and interferon signaling. Interestingly, we
also found 37 modules enriched with the AD KEGG
pathway, e.g. the yellow module of the network for the
brain region PT presented a 3.5-fold enrichment of this
pathway (FDR adjusted P value = 1.56 × 10–19).
The co-expression network analysis identifies gene
modules, i.e. groups of genes, which show highly corre-
lated expression profiles across samples. As a result,
the pattern of correlated expression facilitates reduction
of the module expression profile to one representative
feature, the module eigengene [48], which is specifically
defined as the first principal component of the stan-
dardized module expression data. It has been demon-
strated that eigengenes among different modules often
exhibit correlations, allowing for the construction of
co-expression networks from eigengene expression pro-
files, similar to the construction of these networks
using gene expression data [49]. To investigate how the
network modules in different brain regions interact, we
constructed a co-expression network based on the
eigengene correlations among all the modules in each
brain region gene co-expression network. For simpli-
city, the eigengene based network is referred to as themeta-co-expression network and the modules from the
meta-co-expression network are referred to as meta-
modules.
Fifteen meta-modules were identified from the meta-co-
expression network analysis (Fig. 6 and Additional file 1:
Table S10). Among the meta-modules, 13 were composed
primarily of eigengenes from single brain regions (ranging
from 70 % to 100 % of the meta-module members),
reflecting tissue-specific correlation structures among 13
brain regions. The six brain regions not reflected in the
brain region specific meta-modules are BM10-FP, BM20-
ITG, BM21-MTG, BM22-STG, BM44-IFG, BM8-FC,
and NAc. Eigengenes from these six brain regions par-
ticipated in two different meta-modules: black and blue
(highlighted in Fig. 6). The black meta-module consists
of eigengenes from 17 brain regions, but with roughly
53 % of the eigengenes coming from four brain regions
BM17-OVC (20.3 %), BM20-ITG (11.0 %), BM36-PHG
(11.0 %), and BM38-TP (10.1 %). The blue meta-
modules comprised eigengenes from 18 brain regions,
with brain region BM20-ITG as the major contributor,
accounting for more than 27.3 % of the eigengenes.
We further explored the conservation of modules
across the brain regions by computing the similarity be-
tween all pairs of modules in terms of gene membership
using the Jaccard index measure: A∩Bj j
A∪Bj j
, i.e. the size of the
overlap divided by the size of the union of the gene sets of
two modules A and B. Of all pairs of modules tested, 1037
were found with a Jaccard index > 0.5, suggesting the
presence of putative consensus modules in different brain
regions. Interestingly, the members of the blue meta-
module were enriched for immune response related func-
tional pathways, including immune system, systemic lupus
erythematosus, response to external stimulus, leishmania
infection, allograft rejection, interferon signaling, IL6_7
pathway, and response to stress (Additional file 1: Table
S10), suggesting that immune response is a common and
coordinated feature of the multiple brain regions studied.
Another immune-related gene present in co-expression
modules of 19 brain regions examined was TYROBP the
binding partner of which, TREM2, has recently been
identified in strong association with AD. In the blue meta-
module comprising eigengenes from 18 brain regions,
TYROBP was present in 17 region-specific members.
These observations are not only consistent with historical
observations of immune/inflammation-related dysfunction
in AD, but also with our recent observations of the in-
volvement of immune-related transcripts, such as TYR-
OBP,TREM2, and others [18, 50, 51].
Validation of modules using gene perturbation signatures
As the co-expression network analysis aims to identify co-
regulated modules (or clusters), it is of great interest to
Fig. 6 The meta-co-expression network constructed from module eigengenes identified across 19 brain regions. The lower triangular of the heat
map shows the topological overlap matrix (TOM) while the upper triangular of the heat map shows the eigengene conservation across brain regions
in terms of gene membership as measured by Jaccard index. The outer color bars along the x- and y-axes denote the origin of brain region for each
eigengene and the inner color bar denotes the meta-module membership. Most of the meta-modules are brain region specific except the two
highlighted in rectangles, i.e. blue and black
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capture biological meaningful co-regulation signals rather
than random noise. For this purpose, we identified in vitro
and in vivo gene perturbation signatures and examined
how faithfully the predicted network modules reflected ex-
perimental targets in response to the perturbation of each
gene.
First, we collected a set of Tyrobp gene knock-down
(KD) expression signatures derived from mouse micro-
glia cell lines reported in one of our previous studies
[18]. This Tyrobp KD gene signatures contained 1524
genes which have corresponding human orthologues,
among which 1302 human orthologues were covered by
the current microarray platforms. In the current data-
set, as summarized in Additional file 1: Table S11a, the
KD signatures were significantly enriched with TYR-
OBP-containing modules by at least 1.7-fold (FDR adjusted
P value < 0.012) in all 19 brain regions.Second, we used PSEN1 mutation gene signatures from
a previous study that identified DEGs in familial AD
(FAD) caused by PSEN1 coding mutations [52]. We de-
fined a gene set specific to PSEN1 mutations by excluding
FAD DEGs that were shared with sporadic early onset AD
DEG signatures. PSEN1 gene was represented by four
different probesets in the present microarray platforms.
Fifty-one modules containing one or more PSEN1 probe-
sets were identified across 19 brain regions. Forty-five of
these modules were significantly enriched for PSEN1
mutation signatures at FDR adjusted P value of 0.05
(Additional file 1: Table S11b).
Third, we re-analyzed the data from a previous study
that performed transcriptional profiling of cultured mouse
oligodendrocytes with a deletion of the myelination tran-
scription factor Myrf, myelin regulatory factor, also known
as C11orf9 [53]. The set of genes differentially expressed
in the cells with a Myrf deletion compared with the
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contained MYRF gene across 19 brain regions (Additional
file 1: Table S11c).
Overall, we observed strong enrichment of in vivo and
in vitro gene perturbation signatures in the network
modules harboring the perturbed target. Across different
brain regions, the enrichment in target-harboring mod-
ules was much stronger than that in modules that did
not contain the perturbation target (with one-tailed
Wilcox rank sum test P value = 3.7 × 10–10, 5.8 × 10–5,
and 7.1 × 10–16 for Tyrobp, Myrf, and PSEN1, respect-
ively) (data not shown), suggesting the target genes
(i.e. Tyrobp, Myrf, and PSEN1) and their perturbation
responders tend to be close in the co-expression net-
work and hence clustered in the same module, thus
partly validating the biological meaningfulness of the
network modules being tested in the present data. The
current validation model is not perfect because a single
module cannot capture the whole tissue gene regula-
tory activity. Thus, we were unable to evaluate the
functional role of every module. Nevertheless, the
analyses showed that co-expression modules captured
network sub-structures of meaningful gene–gene inter-
action relationships, which was to some degree vali-
dated in gene perturbation data for the three genes
analyzed here.
Module relevance to AD pathology and severity of clinical
dementia
The co-expression network structures, and the expres-
sion variation underlying the brain networks, collectively
reflect molecular processes associated with AD. How-
ever, beyond a mere association with AD, the relation-
ship of gene expression perturbations and their modular
interrelationships to cognition, cognitive compromise,
and the canonical neuropathological lesions of AD is of
particular and paramount translational interest. To
prioritize the gene modules with respect to their associ-
ation to AD neuropathology, we ranked the modules by
multiple features, including correlations between module
eigengenes and cognitive/pathological traits, and enrich-
ment for gene expression signatures such as the DEGs
and TCGs calculated above. To measure whether mod-
ule and phenotypic traits were correlated, we computed
the Spearman’s correlation coefficient between module
eigengene expression profiles and each trait measure
(i.e. dementia severity (CDR), global probability of AD
pathology (CERAD), cortical NP density (NP and NPrSum,
and neurofibrillary tangle involvement severity (Braak stage
and NTrSum). While the modules could be sorted by each
individual feature of interest, we performed a comprehen-
sive ranking by aggregating the rankings of all features as
described in the “Methods.” The module rankings are pro-
vided in Additional file 1: Table S12. Figure 7 shows theranking of the top 50 modules, with multiple tracks illus-
trating the different properties of the modules, including
ranking score, strength of correlation between eigengene
expression and the six traits, significance of enrichment
with TCGs and DEGs, and correlations among the module
eigengenes.
Table 1 lists the 20 top ranked modules and their brain
regions, top functional terms, and module ranking
scores. Strikingly, six of the 20 top modules are from
one region in the temporal lobe, the inferior temporal
gyrus (BM20-ITG), which is consistent with the fact that
temporal lobe regions ranked top in relevance to disease
as described above. A number of functional pathways
known to be implicated in AD were enriched in the top
ranked modules. These included: an axonal guidance
module (gray17) associated with the superior parietal
lobule (BM7-SPL) ranked number 11; a nervous system
development module (tan) involving the PT ranked
number 12; and a synaptogenesis module (yellow2) in
the inferior temporal gyrus (BM20-ITG) ranked number
15. Two cytoskeleton related pathways are present in the
top ranked modules, including the number 2 module-
tan in BM20-ITG and number 5 module-orchid in the
parahippocampal gyrus (BM36-PHG). The relevance of
these modules is underscored by a growing body of evi-
dence suggesting that tau accumulates preferentially in
axons and may mediate neurotoxicity by altering the
organization and dynamics of the actin cytoskeleton and
abnormalities of the actin cytoskeleton could be critical
in synaptic loss in AD [54, 55]. Two cytoplasm modules
were identified in the top 20, including the number 3
module-blue in the inferior frontal gyrus (BM44-IFG)
and the number 6 module-salmon in the superior frontal
gyrus (BM8-SFG).
In addition to the pathways implicated in AD previ-
ously, we found several novel functional categories
enriched in the top modules. The first category, nu-
cleus, was enriched in the top ranked module, yellow in
the inferior frontal gyrus (BM44-IFG), and also in the
number 8 module (brown) in the superior parietal
lobule (BM7-SPL), number 14 module (green) in the
superior frontal gyrus (BM8-SFG), and number 18
module (brown) in the occipital visual cortex (BM17-
OVC). Nucleus is the organelle of eukaryotic cells in
which chromosomes are housed and genes are tran-
scribed. We also identified three transcription regula-
tion modules in the top modules: red2 and mediumblue
in the inferior temporal gyrus (BM20-ITG) and gray24 in
the precentral gyrus (BM4-PCG). The second category,
biopolymer biological process including biopolymer meta-
bolic process, glycoprotein catabolic process and macro-
molecular complex, was enriched in three modules: the
purple module in the anterior cingulate (BM32-AC), ma-
roon module in the inferior temporal gyrus (BM20-ITG),
Fig. 7 The top 50 ranked modules in the co-expression networks of the 19 brain regions. From outside to inside, the bar chart at track 1 shows
scaled ranking scores, the heat maps at tracks 2–7 show the correlation coefficients (r) between module eigengenes and six cognitive/neuro-
pathological traits (in the order of CDR, Braak, CERAD, mean plaque density, sum of NP density estimates, and sum of NFT density estimates), the
heat maps at tracks 8–13 show − log10(P value) of the enrichment for the DEGs identified for the six traits, the –at tracks 14–19 show − log10(P
value) of the enrichment for the genes correlated with the six traits, and the links in the middle illustrate the significant correlations (FDR < 0.05;
red for correlation > 0.8, blue for correlation < -0.8) among the modules
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meric biomolecules formed in a biological system, such
as polypeptides, polynucleotides, and polysaccharides.
Essentially, the GO categories biopolymer biological
process and cellular component nucleus, which contain
1684 and 1430 genes, respectively, share 706 genes,
suggesting that half of the top modules enriched for the
two GO categories as well as the transcription regulation
pathways likely represented preserved functional networks
across different brain regions. As transcriptional and
translational dysregulation is expected in AD, some or all
members of the biopolymer metabolism/nucleus modules
may play important roles in AD pathogenesis.
Astrocyte-specific, oligodendrocyte-specific, and neuronal-
specific genes are enriched in the top ranked modules
To interrogate the gene expression dataset and determine
whether the top ranked modules could be characterized
by particular cell types, we overlapped the modules topanels of brain cell type-specific genes (Additional file 1:
Table S3). Focusing on the top 20 ranked modules, we
found ten modules were enriched for genes expressed in
specific cell types at a 5 % FDR (Table 1 and Additional
file 1: Table S13). Astrocyte specific genes were
enriched in two nucleus modules (yellow in BM44-IFG
and brown in BM7-SPL) and one module of positive
regulation of cell differentiation (navy in BM20-ITG).
Oligodendrocyte specific genes were enriched in the
number 2 module actin cytoskeleton (tan) from the in-
ferior temporal gyrus (BM20-ITG). The oligodendro-
glial myelin-associated pathways were closely linked to
the AD-associated neuropathology variables, providing
further evidence for targeting oligodendrocyte/myelin
disruption as a new therapeutic option to prevent or re-
verse neuronal impairment leading to AD. Unsurpris-
ingly, neuronal specific genes were enriched in six of
the top ranked modules, including a cytoplasm module
(blue in BM44-IFG), a membrane module (blue in
Table 1 The 20 top ranked modules
Region Module Top GO annotation term Cell type specificity Risk genes enrich.a Score Rank
BM44-IFG Yellow Nucleus Astrocytes IGAP 1 1
BM20-ITG Tan Actin cytoskeleton Oligodendrocytes Aβ 0.89 2
BM44-IFG Blue Cytoplasm Neurons IGAP, Aβ 0.62 3
BM20-ITG Red2 Positive regulation of transcription from RNA polymerase II
promoter
- 0.6 4
BM36-PHG Orchid Cytoskeleton organization and biogenesis - - 0.56 5
BM8-SFG Salmon Cytoplasm - IGAP, Aβ 0.51 6
BM20-ITG Mediumblue Regulation of transcription DNA dependent - - 0.5 7
BM7-SPL Brown Nucleus Astrocytes IGAP 0.5 8
BM32-AC Purple Biopolymer metabolic process - IGAP 0.46 9
BM8-SFG Blue Membrane Neurons IGAP, Aβ 0.46 10
BM7-SPL Gray17 Axon guidance - - 0.43 11
PT Tan Nervous system development Neurons IGAP 0.43 12
BM20-ITG Maroon Glycoprotein catabolic process - Aβ 0.4 13
BM8-SFG Green Nucleus - IGAP 0.39 14
BM20-ITG Yellow2 Synaptogenesis - - 0.39 15
BM8-SFG Pink Nuclear part Neurons Aβ 0.39 16
BM20-ITG Navy Positive regulation of cell differentiation Astrocytes - 0.38 17
BM17-OVC Brown Nucleus Neurons IGAP, Aβ 0.38 18
BM4-PCG Gray24 Regulation of transcription - - 0.38 19
PT Yellow Macromolecular complex Neurons IGAP, Aβ 0.37 20
a Indicating whether IGAP or Aβ network genes were enriched in the module
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in PT), a nuclear part module (pink in BM8-SFG), a nu-
cleus module (brown in BM17-OVC), and one macromol-
ecular complex module (yellow in PT). Strong enrichment
of astrocyte-specific, oligodendrocyte-specific, and
neuron-specific genes in the top ranked modules is con-
sistent with the observation that genes specific to these
cell types were enriched for differential expression signa-
tures as shown above. Identification of potential cell types
in the top ranked modules associated with AD pathology
argues for the development of interventions that target
specific molecular pathways in homogeneous cells with in-
creased precision devoid of heterogeneous variation.
The top ranked network modules were preserved in an
independent (Harvard) brain bank AD dataset
To validate the top ranked networks constructed from
the 19 brain regions described herein, we performed in
silico analysis of an independent dataset (Fig. 1b). The
top ranked modules were first projected onto co-
expression networks constructed from the independent
Harvard brain bank (HBB) AD dataset [18] to verify
whether the top modules were replicable. We assem-
bled the co-expression networks constructed from a
combined transcriptome profiling of three brain re-
gions, dorsolateral prefrontal cortex (PFC), visualcortex (OVC), and cerebellum (CB), in 376 late onset
AD patients of the HBB AD cohort [18]. For conveni-
ence, the network modules identified from the present
study sample were referred to as MSBB modules while
the network modules from the HBB dataset were re-
ferred to as HBB modules. We compared the networks
identified from the two datasets and found that 37 %
and 25 % of the MSBB modules from BM46-PFC and
BM17-OVC, respectively, significantly overlapped with
the HBB networks at FDR < 0.05. Conversely, 47 % and
34 % of the HBB modules significantly overlapped with
the MSBB BM46-PFC and BM17-OVC networks, re-
spectively. On the other hand, 36 % of all the 1558
MSBB modules significantly overlapped with the HBB
networks (Additional file 2: Figure S3) while 77 % of
the HBB modules were significantly overlapping with
the MSBB networks. If we considered the rankings of
networks in relevance to AD pathology in the two data-
sets, 35.9 % of the top 5 % MSBB modules significantly
overlapped with the top 5 % HBB modules, suggesting
high consistency of network rankings between inde-
pendent datasets despite the fact that the HBB data
contain only late-stage AD patients while the MSBB
data contain the full spectrum of disease status/severity
including specimens from normal individuals, persons
meeting criteria for mild cognitive impairment and
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associated neuropathology.
Among the top 20 ranked MSBB modules, 13 signifi-
cantly overlapped with six of the top 20 HBB modules
(Additional file 1: Table S14). The most enriched HBB
modules were primarily enriched for nerve ensheath-
ment (an oligodendroglial/myelin pathway), cytoskeletal
protein binding, cell junction, exocytosis, and oxidoreduc-
tase activity, while the corresponding preserved MSBB
modules were enriched for actin cytoskeleton, glycopro-
tein catabolic process, cytoplasm, nucleus, regulation of
transcription DNA dependent, nervous system develop-
ment, macromolecular complex, and biopolymer meta-
bolic process. Taken together, these results highlighted the
preserved networks that are promising as targets for the
treatment of AD pathology.The top ranked modules were enriched for AD genetic risk
factors
The top ranked networks identified above could either
play a causal role in AD or be reactive to or independent
of the disease. While postmortem gene expression studies
cannot directly assess causality of the top ranked networks
given by themselves, combinatorial analyses with genetic
datasets can help address this question, at least partially.
We tested whether the modules identified through ana-
lysis of gene expression were enriched for known AD gen-
etic risk factors identified from genome-wide association
studies (GWAS). We used a set of AD susceptibility genes
from a large scale meta-analysis by the International Gen-
omics of Alzheimer’s Project (IGAP) [56]. We screened
for candidate single nucleotide polymorphisms (SNPs)
with a nominal P value less than 0.05 and then extracted
genes near any of the candidate SNPs. We used the re-
laxed significance threshold for the IGAP gene set with
the aim of including de novo causal gene loci of small ef-
fect sizes that were unable to exceed the genome wide sig-
nificance due to insufficient statistical power. A recent
study demonstrated that combining genes with nominally
significant GWAS P values and tissue-specific networks
were powerful in building machine learning classifiers for
identifying novel genes associated with disease [57]. There
was a total of 864 IGAP nominally associated genes
that were also profiled in the current microarray gene
expression dataset. Table 1 and Additional file 1: Table
S15 summarized the enrichment of the IGAP gene sets
in the top 20 ranked MSBB modules at an FDR < 5 %.
Ten modules from six brain regions were significantly
enriched for the IGAP gene set. Four of these modules
belonged to the nucleus subnetworks and five were
enriched for neuron cell type-specific genes. The top
module, yellow from the BM44-IFG network, which
was astrocyte cell type-specific and annotated withnucleus function category, was 1.5-fold enriched for
IGAP genes (FDR adjusted P value = 1.6 × 10–4).
One prevalent pathology hypothesis of AD is accumu-
lation of toxic Aβ cascade in the brain. Since its formu-
lation in the early 1990s, the amyloid hypothesis has
been somewhat refined but remains the most influential
conceptual framework for AD [58]. Centered on Aβ,
Campion et al. manually curated a biological network of
335 genes/proteins which have been shown to interfere
with Aβ production, clearance, aggregation, or toxicity,
including amyloid precursor protein APP, beta-secretase
BACE1, gamma-secretases PSEN1/PSEN2, and Aβ clear-
ance proteins like APOE and CLU (reviewed in [59]). Of
these 335 genes, 330 were profiled by the current
microarray dataset. We assessed whether the 330 Aβ-
centered biological network genes were enriched in the
top 20 modules and found significant overrepresenta-
tion in eight top modules as summarized in Table 1
and Additional file 1: Table S16. Interestingly, five of
the eight modules overrepresented with Aβ-centered
biological network genes were also enriched for IGAP
GWAS gene sets (Table 1), including blue in BM44-
IFG, salmon and blue in BM8-SFG, brown in BM17-
OVC, and yellow in PT. Note that the APP gene was
present in one module, blue in BM44-IFG. APOE was
present in two modules: blue in BM8-SFG and brown
in BM17-OVC. Enrichment of the Aβ-centered network
in the top modules provided additional support of the
relevance of these modules regarding AD pathology.
The strong enrichment of AD genetic risk factors and
Aβ-centered network within the top modules further
reinforce their strong association with AD. On the other
hand, this also identifies other members of these modules
that may not only have critical roles in Aβ production and
processing, but also represent upstream mechanism that
drive Aβ and other pathological processes.
Selective vulnerability of brain regions in AD
Functional neuroimaging and neuropathological analyses
have shown that different brain regions may have different
vulnerability to AD. One of the outstanding questions in
studying AD is when (i.e. under what conditions) and
where (i.e. which brain regions) the disease emerges. Since
this MSBB cohort consists of the subjects from a full
spectrum of normal, low, and high severity staging with
respect to each cognitive/dementia and neuropathological
trait, we explored further the temporal and spatial pat-
terns of the disease by intersecting the gene signatures
associated for each trait and the co-expression modules,
to relate region-specific subnetworks to the molecular
changes at different stage of dementia and neuropathol-
ogy. As an example, we examined two functional cat-
egories across all brain regions: nucleus and actin
cytoskeleton, which were enriched in the top two
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modules for relevance to AD pathology (Table 1). For
each of the 19 brain regions examined, we screened for
the MSBB modules significantly enriched for the gene
sets related to the two functional categories (FDR <
0.05) and then picked the MSBB module with the high-
est ranking as the representative of the brain region
with respect to the given functional category. We
sorted the 19 regions by their region-specific ranking of
the representative modules. Meanwhile, we intersected
these region-specific representative modules with the
previously defined DEG signatures. The results are
shown in the bar charts while the intersections between
the modules and the DEG signatures are shown in the
heat maps in Fig. 8.
Overall, the analysis of region-specific subnetworks
showed that different brain regions were affected differ-
ently in AD in light of biological processes ranking and
enrichment of DEGs. For the nucleus subnetworks, theFig. 8 Selective vulnerability of the 19 brain regions to AD as exemplified b
(bottom panel) subnetworks. The bar charts on the left, as colored by the re
The two heat maps illustrate the enrichment of the DEG signatures in the c
FDR corrected P value of the enrichment test for a module and a DEG signinferior frontal gyrus (BM44-IFG) was ranked at the
top, followed by the superior frontal gyrus (BM8-SFG),
the superior parietal lobule (BM7-SPL), and the anter-
ior cingulate (BM32-AC). For the actin cytoskeleton
subnetworks, the inferior temporal gyrus (BM20-ITG)
was ranked at the top, followed by the inferior frontal
gyrus (BM44-IFG), the temporal pole (BM38-TP), and
the PT. The subnetworks enriched for the nucleus
genes were enriched for differential expression signatures
in 16 brain regions. Specifically, the DEGs between the
high and low CDR groups were enriched in nine brain
region-specific subnetworks, with upregulation or down-
regulation directions varying among brain regions, sug-
gesting dysregulation of nucleus genes was more likely to
be involved in the advanced stage as defined by dementia
severity (CDR). For the traits including Braak neurofibril-
lary pathology stage, CERAD, sum of NP density esti-
mates, and mean plaque density, we found enrichment for
the upregulated DEGs between the low and normaly actin cytoskeleton (top panel) and biopolymer metabolic process
presentative modules’ name, show the region-specific ranking orders.
orresponding co-expression modules. The color intensity shows the
ature at minus log10 scale
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and low groups in multiple region-specific subnetworks,
suggesting an elevated expression of the nucleus genes
in the early stage but reduced expression of the path-
way in advanced stage of AD with respect to those
traits. Only five region-specific actin cytoskeleton sub-
networks showed significant enrichment for DEGs, in-
cluding the upregulated genes of high–low for Braak
neurofibrillary pathology stage, CDR, sum of NP dens-
ity estimates, and mean plaque density, in regions
BM44-IFG, BM21-MTG, BM38-TP, and PT. Specific-
ally, the subnetwork from the top ranked region BM20-
ITG was enriched for upregulated DEGs of low–normal
as defined by Braak and CERAD, suggesting the upreg-
ulation of actin cytoskeleton gene expression might
emerge in the early stage (low severity) of disease pro-
gression for this particular region. A parsimonious in-
terpretation of these directional changes implicates the
region specific pattern of degeneration of cells in the
late stages of the disease and the processes that are at
play early in the disease before significant degeneration
ensues. These opposing directional changes in gene ex-
pression based on the early versus late stages of disease
highlight the power of this dataset which includes speci-
mens from donors in early stages of disease progression.
A focus on the transcriptional changes that accompany
the early stages of AD could help identify not only transla-
tional treatment targets associated with disease onset, but
also suggest the direction of change that treatments
should induce to counter disease progression.
Discussion
This is the first large-scale study to characterize gene ex-
pression regulations and also gene transcriptional net-
works in multiple regions of each neocortical lobe and
in subcortical structures in AD. Among the unique fea-
tures of the present sample cohort is that it contains a
continuum spectrum of clinical and neuropathological
disease stages from normal to severe. These two features
have allowed us to systematically examine the spatial
and temporal patterns of molecular pathways and mod-
ules in varying physiological states of the disease. We
identified more than 6000 probesets which were differ-
entially expressed as a function of cardinal phenotypic
features of AD in multiple brain regions (Additional file
1: Table S4a) and also rank-ordered co-expression net-
work modules relevant to AD pathology. By making use
of a large-scale human brain single-cell RNA-seq data-
set, we identified signatures and network modules with
overrepresentation of gene transcripts expressed pre-
dominantly in neurons, oligodendrocytes, and astrocytes.
To conduct a comprehensive evaluation of the relative
involvement of the genes in AD, we ranked the genes by
assembling the strengths of association with every traitin every brain region, using a similar ranking metric as
that used for network (Additional file 3: Table S17).
Genes are known to be organized into functional net-
works according to cellular processes and pathways and
gene co-expression networks are able to characterize
coordinated transcriptional relationships between gene
transcripts in various biological contexts including
complex diseases [19]. The present study utilizes an in-
tegrative network analysis to highlight and prioritize
pathways and gene targets underlying AD at different
stages of dementia and neuropathology. We rank-ordered
the 19 brain regions by systematically comparing the
number of gene signatures identified for six phenotypic
traits encompassing the cognitive, NFT, and NP dimen-
sions. Interestingly, several top ranked regions (BM36-
PHG, BM20-ITG, and BM21-MTG) are located in the
temporal lobe including the perirhinal cortex (Fig. 5), a
region where tangle pathology is thought to develop early
in the disease process. Consistently, half of the top 20
modules were from these same regions, highlighting the
significance of these regions in light of disease pathology
at the functional pathway level. We verified that the top
modules were more likely to be preserved and more than
half of them were showing significant overlap with the
top ranked modules in an independent AD dataset,
underscoring the power of integrative network analysis
in revealing functional modules/pathways underlying
the disease traits. We identified well established path-
ways implicated in AD, such as nervous system devel-
opment, axon guidance, and cytoskeleton, among the
top modules expressed in neurons, oligodendrocytes,
and astrocytes. In addition, we also identified less stud-
ied pathways including biopolymer metabolism and nu-
cleus, providing novel pathway level target to enhance
our understanding of the molecular regulation of the
disease.
The adult human brain is a complex tissue, comprising
multiple cell types with different functions, topologies,
and molecular characteristics. As different cell types might
present different vulnerability to brain disorder, it is of
great value to dissect cell type signals and identify cell
type-specific expression change [25, 26, 60]. We utilized a
set of cell type-specific genes to identify which cell type-
specific marker genes were enriched in the DEGs and the
top modules. While tissue homogenate-based postmortem
studies preclude definitive resolution of cell type-specific
contributions to the disease, the current analysis revealed
astrocytes, oligodendrocytes, and neurons specific genes
to be enriched for dysregulation. Although the involve-
ment of neurons in the disease process is obvious and ex-
pected, a prominent role for the involvement of astrocytes
and oligodendrocytes has been postulated less frequently.
We also assessed the regional specificity of cell type ex-
pression changes. Specifically, the inferior temporal gyrus
Wang et al. Genome Medicine  (2016) 8:104 Page 19 of 21(BM20-ITG) was enriched primarily for upregulated genes
which were overrepresented with oligodendrocyte-specific
genes (Additional file 1: Table S6), suggesting that the
changes in the nerve ensheathment/oligodendrocyte
emerge in this region at an early stage of dementia. Oli-
godendrocytes coat axons with a fatty sheath of myelin,
which promotes faster communication between neurons.
Recent evidence suggests that insufficient axon myelin-
ation or inability to adequately maintain extant myelin by
oligodendrocytes might render the affected axonal pro-
cesses vulnerable to disease-related damage, such as
inflammation, oxidative stress, fibrillogenic Aβ, or to
phospho-tau species [61]. Additionally, since oligodendro-
cytes have been implicated in maintaining axonal integrity,
their dysfunction could contribute to neurodegeneration
directly. We hypothesize that the disruption of nerve en-
sheathment/myelin integrity is an early indicator of AD
pathology in certain brain regions such as BM20-ITG.
The complex relationship among over 1000 co-
expressed gene modules built from 1053 postmortem
brain tissues across 19 brain regions was summarized
by a meta-co-expression network based on correlations
between module eigengene expression profiles. The ma-
jority of the meta-modules were brain region specific, i.e.
dominated by eigengenes from one brain region, reflect-
ing, on the one hand, strong gene expression correlation
within brain regions, and on the other hand, possibly the
difference in the biological functions that different brain
regions play. However, significant correlations among
brain regions were also detected. Specifically, two meta-
modules were identified as comprising highly correlated
consensus network modules from at least 17 brain regions
and these consensus modules were enriched primarily for
immune response related functional pathways. This result
suggests the immune response is regulated in a coordi-
nated way in different areas of the brain and/or as a result
of AD progression throughout the brain. Increasing evi-
dence suggests strong interactions with immunological
mechanisms in AD pathogenesis. For example, a number
of genes expressed in immune cells of the central nervous
system (CNS) carry genetic variants associated with in-
creased risk of AD, including CD33 [62],TREM2 [63], and
CR1 [64].
GWAS have been widely employed to identify genetic
variants influencing risk for complex diseases, including
AD. Although a number of genetic risk loci have been
identified, the functional variants and specific genes re-
main elusive for most loci [65]. Transcriptional profiling
enables the capture of a multidimensional view of this
complexity, reflecting the interplay of genomic and envir-
onmental effects. We examined the expression regulation
of 34 AD susceptibility genes and found four genes,
PSEN1, MEF2C, PICALM, and PLD3, to be differentially
expressed in several regions primarily in the advancedstage of disease. While most of the AD susceptibility genes
showed no evidence of expression changes, this highlights
a big gap between genetic factors and transcription regula-
tions in a complex disease such as AD, further supporting
the use of the network analysis that leads to discovery of
subnetworks associated with AD clinical and pathological
traits.
Conclusions
In summary, this study provides a comprehensive pan-
cortical analysis of genome-wide genes and gene co-
expression structures associated with AD pathology in
an unprecedented number of brain samples collected
from well-characterized individuals with a continuum
spectrum of dementia and neuropathology. For the first
time we were able to systematically rank-order 44,692
gene probesets, 1558 co-expressed gene modules, and
19 brain regions based upon their association with six
AD cognitive and pathological traits. The higher-order
network organization of transcriptome uncovered by
this study not only narrows down generic pathways to
disease-associated specific gene modules but also
pinpoints individual genes across 19 brain regions. We
validated the network topology of modules using per-
turbation signatures. More than half of the top ranked
gene modules were enriched for AD risk genes and rep-
licated in another independent AD study cohort, fur-
ther demonstrating the validity and novelty of this
study. Such results provide functional contexts for AD
risk genes and enable the development of novel hy-
potheses for further experimental validation. We com-
puted human brain cell type-specific genes from single-
cell RNA-seq data and then identified DEG signatures
and top network modules specific to neurons, oligo-
dendrocytes, and astrocytes. This study has not only
identified novel networks and pathways associated with
AD but it has also provided new insights into promin-
ent molecular mechanisms underlying selective re-
gional vulnerability to AD. The data, the results, and
the findings from this study have painted a global pic-
ture about changes in gene expression and gene–gene
interactions in AD and will facilitate future research on
the molecular mechanisms of this complex disease and
potentially aid in the development of treatment strat-
egies that can target molecular events associated with
the earliest documentable stages of disease onset.Additional files
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